Impact of histological subtype on outcomes of renal cell carcinoma patients

References

• GLOBOCAN. Available from: globocan.iarc.fr [cited 2016 Nov 27 ].
   Google Scholar
• Abdel-Rahman O. Squamous cell carcinoma of the bladder: a SEER database analysis. Clin Genitourin Cancer. 2017;15(3):e463-e468.
   PubMed Web of Science ®Google Scholar
• Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology. 2007;39:459–465.
   PubMed Web of Science ®Google Scholar
• Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015;48:166–174.
   PubMedGoogle Scholar
• Abdel-Rahman O. Impact of tumor size on the outcome of patients with small renal cell carcinoma. Expert Rev Anticancer Ther. 2017;17:769–773.
   PubMed Web of Science ®Google Scholar
• Su D, Singer EA, Srinivasan R. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology. Curr Opin Oncol. 2015;27:217–223.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol. 2017.
   Web of Science ®Google Scholar
• Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37:1469–1489.
   PubMed Web of Science ®Google Scholar
• Kokabi N, Xing M, Duszak R, Jr, et al. Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. J Comp Eff Res. 2016;5:441–452.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Risk of subsequent primary kidney cancer after another malignancy: a population-based study. Clin Genitourin Cancer. 2017;15:e747–e754.
   PubMed Web of Science ®Google Scholar
• Simone G, Tuderti G, Ferriero M, et al. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes. Eur J Surg Oncol. 2016;42:1744–1750.
   PubMed Web of Science ®Google Scholar
• Smaldone MC, Egleston B, Hollingsworth JM, et al. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. Med Care. 2016;55:398–404.
   Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results Program. About the SEER Program. Available from: http://seer.cancer.gov/about [cited 2016 June 25].
   Google Scholar
• Tyson MD, Humphreys MR, Parker AS, et al. Age-period-cohort analysis of renal cell carcinoma in United States adults. Urology. 2013;82:43–47.
   PubMed Web of Science ®Google Scholar
• King SC, Pollack LA, Li J, et al. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol. 2014;191:1665–1670.
   PubMed Web of Science ®Google Scholar
• Olshan AF, Kuo TM, Meyer AM, et al. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med. 2013;2:744–749.
   PubMed Web of Science ®Google Scholar
• Lee S, Jeon HG, Kwak C, et al. Gender-specific clinicopathological features and survival in patients with renal cell carcinoma (RCC). BJU Int. 2012;110:E28–E33.
   PubMed Web of Science ®Google Scholar
• Daugherty M, Blakely S, Shapiro O, et al. Chromophobe renal cell carcinoma is the most common nonclear renal cell carcinoma in young women: results from the SEER database. J Urol. 2016;195:847–851.
   PubMed Web of Science ®Google Scholar
• Schwartz K, Ruterbusch JJ, Colt JS, et al. Racial disparities in overall survival among renal cell carcinoma patients with young age and small tumors. Cancer Med.. 2016;5:200–208.
   PubMed Web of Science ®Google Scholar
• Patel HD, Kates M, Pierorazio PM, et al. Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: a comorbidity controlled competing risks model. Urol Oncol. 2014;32:576–583.
   PubMed Web of Science ®Google Scholar
• Aron M, Nguyen MM, Stein RJ, et al. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 2008;54:133–140.
   PubMed Web of Science ®Google Scholar
• Lai H, Lai S, Krongrad A, et al. The effect of marital status on survival in late-stage cancer patients: an analysis based on surveillance, epidemiology, and end results (SEER) data, in the United States. Int J Behav Med. 1999;6:150–176.
   PubMed Web of Science ®Google Scholar
• Keegan KA, Schupp CW, Chamie K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012;188:391–397.
   PubMed Web of Science ®Google Scholar
• Roos FC, Steffens S, Junker K, et al. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer. 2014;14:372.
   PubMed Web of Science ®Google Scholar
• Daugherty M, Bratslavsky G. Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database. Urol Oncol. 2014;32:549–554.
   PubMed Web of Science ®Google Scholar
• Hellenthal NJ, Mansour AM, Hayn MH, et al. Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care. J Urol. 2011;185:415–420.
   PubMed Web of Science ®Google Scholar
• Shuch B, Hanley J, Lai J, et al. Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer. 2013;119:2981–2989.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature. Crit Rev Oncol Hemat. 2015;94:238–250.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Taksey JD, et al. Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib. J Clin Oncol. 2012;30(5 Suppl):437.
   Google Scholar
• Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2016;5:169–181.
   PubMed Web of Science ®Google Scholar
• Shah BK, Ghimire KB. Survival trends among patients with advanced renal cell carcinoma in the United States. Urol Int. 2015;94:133–136.
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Vankayala H, Vigneau FD, et al. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer. 2014;12:124–129.
   PubMed Web of Science ®Google Scholar
• Malouf GG, Ali SM, Wang K, et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol. 2016;70:348–357.
   PubMed Web of Science ®Google Scholar